Navigation Links
Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C


Albuferon 1200-mcg Every Two Weeks (Albuferon 1200 Q2w)

-- ITT analysis shows that 55.5% of patients in the Albuferon 1200 Q2w

treatment group achieved SVR, vs. 57.9% for peginterferon alfa-2a

administered every week.

-- In heavier patients (75 kg or heavier) who were treatment-adherent,

67.9% of those in the Albuferon 1200 Q2w treatment group achieved SVR,

versus 53.3% for peginterferon alfa-2a every week.

-- Among all treatment-adherent patients in the Albuferon 1200 Q2w

treatment group, 70.6% achieved SVR, versus 66.7% for peginterferon


-- ITT analysis shows that the Albuferon 1200 Q2w treatment group

exhibited a robust early antiviral response (reduction in hepatitis C

RNA viral load to below the level of quantitation): 74.5% for

Albuferon 1200 Q2w at Week 12, vs. 65.8% for peginterferon alfa-2a.

The Albuferon 1200 Q2w treatment group also had the most rapid time to

HCV RNA negativity.

-- The rate of discontinuations due to adverse events was 18.2% in the

Albuferon 1200 Q2w treatment group, vs. 6.1% in the peginterferon alfa-

2a group. Adverse events observed were those typically expected with

interferon therapy. Dose reductions were attempted in only 24.4% of

Albuferon subjects prior to discontinuation, versus 42.9% for

peginterferon alfa-2a. Adverse events observed were those typically

expected with interferon therapy.

"In the Albuferon Phase 3 trials, we are strongly encouraging titration of dose where necessary to increase tolerability, reduce the rate of discontinuations, and maximize the therapeutic benefit of the robust early antiviral response offered by the 1200-microgram dose on a two-week administration schedule," said Dr. Stump.

Albuferon 1200-mcg Monthly (Albuferon 1200 Q4w)

-- ITT analysis shows that 50.9% of patients in the Albuferon

SOURCE Human Genome Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
(Date:10/9/2015)... 9, 2015 AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ... the annual European Society of Emergency Medicine (EuSEM) meeting to ... , 2015 at the Lingotto Congress Centre in ... meeting of emergency medicine practitioners in the world with over ... Data from the previously announced phase 2 bunionectomy trial will ...
(Date:10/9/2015)... LAUSANNE , Suiza, October 9, 2015 El ... Yutaka Kondo y Junko Takita ... se ha otorgado a los doctores Yutaka Kondo ... El ,JCA-Mauvernay Award 2015, se ha otorgado a los ... Junko Takita    ™ , una compañía biofarmacéutica global con ...
(Date:10/8/2015)... 8, 2015  Ardelyx, Inc. (NASDAQ: ARDX ... and cardio-renal diseases, today announced that clinical data ... be presented at the 2015 American College of ... measures of sustained response in IBS-C patients enrolled ... Phase 2 trial. The meeting will be held ...
Breaking Medicine Technology:
(Date:10/9/2015)... ... October 09, 2015 , ... ... was recognized by Cabarrus County Active Living and Parks for its outstanding commitment ... company’s dedication to consistently going above and beyond the call of duty, ...
(Date:10/9/2015)... ... October 09, 2015 , ... ... Post, CPA , as Chief Financial Officer. Kimberly will provide leadership and ... with any strategic acquisitions. Kimberly’s experience guiding healthcare services organizations through significant ...
(Date:10/9/2015)... , ... October 09, 2015 , ... ... pleased to announce it will sponsor the upcoming Cisco Georgia Partner Appreciation Event. ... Complex on the campus of Georgia Tech, in Atlanta, Georgia. , This year’s ...
(Date:10/8/2015)... ... October 09, 2015 , ... The Guthrie ... this November. The support post-concussion group was started by Steven Hicks, a Licensed ... member. The group was started in November 2010 to help support ...
(Date:10/8/2015)... ... October 08, 2015 , ... Florida Hospital, the Exclusive Hospital of the Tampa ... 5K Run/Walk benefitting breast cancer research and patient services. The race is expected to ... 11th at Raymond James Stadium prior to the Bucs game versus the Jacksonville Jaguars, ...
Breaking Medicine News(10 mins):
... an inherited disease that clogs airways with thick mucous, ... life expectancy for children with cystic fibrosis has increased ... shortened in young adulthood by the ravages of lung ... common, environmental microbes that mutate in ways that let ...
... are offering pediatric patients diagnosed with chronic illnesses acupuncture ... effects like nausea, fatigue, and vomiting caused by chronic ... Chinese and Western medicine at Rush Children,s Hospital is ... acupuncture might help in reducing pain in children and ...
... ... to address childhood obesity, a risk factor for a number of chronic diseases including diabetes, ... ... today launched a major campaign to address childhood obesity, a risk factor for a number ...
... , ... Sunquest Collection Manager™ increases patient safety through accuracy and timeliness , ... (PRWEB) February 9, ... and outreach solutions, announced today that the University of Virginia Health System Medical ...
... recurrence-free, research shows , TUESDAY, Feb. 9 (HealthDay News) ... play a part in prognosis with non-small cell lung cancers, ... of the patient. , The researchers analyzed genetic and clinical ... on sex and age (below or above age 70). The ...
... begins in the womb, expert says, , TUESDAY, Feb. 9 ... of milk and have a high dietary intake of vitamin ... multiple sclerosis later in life, researchers say. , The new ... their experiences and diet during pregnancy. The nurses were followed ...
Cached Medicine News:
... Anatomical Malar I Implants - Providing the ... follows the contour of the zygoma while ... Anatomical Malar II Implants - The ... surgeon with another augumentation option that adds ...
Chin Implants are used for cosmetic augmentation, repairing trauma related injuries and genetic deficiencies. They are inserted through an incision in the mouth below the incisor teeth or through an ...
... FL40 Centrifuge Series from Thermo Electron ... increase your productivity in the lab. ... rotors and accessories for high-volume blood ... IEC CL40 and FL40 Centrifuge Series ...
Medicine Products: